TY - JOUR
T1 - Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients
AU - Mata-Marín, José A.
AU - Méndez-Cruz, René
AU - Arroyo-Anduiza, Carla I.
AU - Mata-Marín, Luis A.
AU - Gaytán-Martínez, Jesús
AU - Asbún-Bojalil, Juan
PY - 2013/8
Y1 - 2013/8
N2 - The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment.
AB - The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment.
KW - Antiretroviral therapy
KW - Endothelial damage
KW - Patients infected with HIV
UR - http://www.scopus.com/inward/record.url?scp=84879154489&partnerID=8YFLogxK
U2 - 10.1002/jmv.23624
DO - 10.1002/jmv.23624
M3 - Artículo
C2 - 23765771
SN - 0146-6615
VL - 85
SP - 1321
EP - 1326
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 8
ER -